Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2008 1
2009 1
2010 2
2011 8
2012 5
2013 2
2014 2
2015 3
2017 6
2018 9
2019 5
2020 6
2021 6
2022 1
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study.
Rottenburger C, Hentschel M, Fürstner M, McDougall L, Kottoros D, Kaul F, Mansi R, Fani M, Vija AH, Schibli R, Geistlich S, Behe M, Christ ER, Wild D. Rottenburger C, et al. Among authors: fani m. EJNMMI Res. 2024 Apr 6;14(1):37. doi: 10.1186/s13550-024-01101-w. EJNMMI Res. 2024. PMID: 38581480 Free PMC article.
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum.
Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, Geistlich S, Borgna F, Fani M, Bernhardt P, van der Meulen NP, Müller C, Schibli R, Wild D. Fricke J, et al. Among authors: fani m. Eur J Nucl Med Mol Imaging. 2024 Mar 7. doi: 10.1007/s00259-024-06641-w. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38448550 No abstract available.
Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.
Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner F, Templeton A, Schäfer N, Wild D, Chirindel A; all investigators on behalf of the SSNM Therapy Working Group. Neubauer MC, et al. Among authors: fani m. Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1185-1193. doi: 10.1007/s00259-023-06536-2. Epub 2023 Dec 1. Eur J Nucl Med Mol Imaging. 2024. PMID: 38038755 Free PMC article.
61Cu-Labeled Radiotracers: Alternative or Choice?
Fani M, Nicolas GP. Fani M, et al. J Nucl Med. 2023 Dec 1;64(12):1855-1857. doi: 10.2967/jnumed.123.266171. J Nucl Med. 2023. PMID: 37884329 Free PMC article. No abstract available.
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.
Grand-Guillaume J, Mansi R, Gaonkar RH, Zanger S, Fani M, Eugster PJ, Beck Popovic M, Grouzmann E, Abid K. Grand-Guillaume J, et al. Among authors: fani m. J Transl Med. 2023 Sep 7;21(1):604. doi: 10.1186/s12967-023-04466-z. J Transl Med. 2023. PMID: 37679770 Free PMC article.
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.
Opalinska M, Lezaic L, Decristoforo C, Kolenc P, Mikolajczak R, Studen A, Simoncic U, Virgolini I, Trofimiuk-Muldner M, Garnuszek P, Rangger C, Fani M, Glowa B, Skorkiewicz K, Hubalewska-Dydejczyk A. Opalinska M, et al. Among authors: fani m. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4110-4111. doi: 10.1007/s00259-023-06335-9. Epub 2023 Jul 15. Eur J Nucl Med Mol Imaging. 2023. PMID: 37452871 Free PMC article. No abstract available.
65 results